Insider filing
Traded Nov 16 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Nov 9, 2026 · Filed Nov 12, 2026
A Cytokinetics director sold $141K of Cytokinetics shares. The filing says it was made under a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$141,189
Shares × reported transaction price
5 days after results of Nov 4, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $55.14 on Nov 9, 2026, within 3% of its 52-week low, after a 17% drop over the previous 30 trading days
52-week range $53.69 (Nov 6, 2026) to $87.26 (Jun 29, 2026), 4% of the way up, from 251 adjusted closes. 30 trading days earlier: $66.16 on Sep 28, 2026. Describes the past only, not a forecast
RSI 32, 21% under its 200-day average, 16% under its 50-day average, 37% below the 52-week high, 20-day volatility 57% a year, against the S&P 500: −9 points over 1 month, −26 points over 3 months, −28 points over 6 months
From the adjusted closes up to Nov 9, 2026. RSI: Wilder's 14-day relative strength index (0 to 100). Averages: the last 50 and 200 closes. Volatility: standard deviation of the last 20 daily returns, annualised. S&P 500: the stock's move minus SPY's between the same dates (21, 63 and 126 trading days). Describes the past only, not a forecast
Filing box checked: sold under a Rule 10b5-1 plan
Only flagged when a footnote says so; never inferred
FDA approved Myqorzo on Nov 13, 2026, 4 days after this trade.
New use approved (efficacy supplement). Active ingredient: Aficamten. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −9.5% | −8.6% | −1.0% |
Past results only. Not a forecast.
Insider filing
Traded Nov 16 · filed 3 days later
Derivative exercise or conversion — not an open-market buy.
Robert I Blum (President & CEO) sold ~$270K of Cytokinetics
Planned saleRobert I Blum (President & CEO) sold ~$120K of Cytokinetics
Planned saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.